The Pulse
Anthropic and OpenEvidence Bring Clinical AI to About 100 Countries
Anthropic and OpenEvidence are rolling out free clinical decision support for healthcare providers in about 100 countries. OpenEvidence will adapt the service to regional conditions, while Anthropic supplies backend technology.
AI.info Team ·
A rollout spanning about 100 countries
About 100 countries are included in Anthropic and OpenEvidence’s plan to offer free AI-powered clinical decision support to healthcare providers, according to a country list supplied by OpenEvidence. The companies announced the collaboration on September 22, with Uganda, Angola, Sudan, Haiti and Mongolia among the named destinations.
OpenEvidence answers doctors’ questions using peer-reviewed medical research and treatment guidelines. It is already free to clinicians in the United States and Europe; the new initiative brings a specialized version to countries where access to medical literature, specialist expertise and continuing medical education can be limited.
The companies have not disclosed the financial terms. Anthropic will provide backend technology, while OpenEvidence says it will adapt the system for regional healthcare conditions.
Local conditions shape the product
Adapting the service matters because clinical decisions depend on more than published evidence. Disease patterns, diagnostic resources and available treatments can vary from those in wealthier countries, and clinical AI trained mainly on data from high-income settings may not match local practice.
OpenEvidence said it had already been working with health organizations in Rwanda and Botswana on adapting its tools to those differences. Its founder, Daniel Nadler, described the approach this way:
“One hundred percent of what we are building for these places is context adaptive.”
Daniel Nadler, founder of OpenEvidence, speaking to Reuters
Nadler also pointed to smartphone access as a potential route into settings where medical facilities lack round-the-clock electricity. The report did not say how the product will perform when connectivity is poor, or detail how local clinicians and health authorities will shape its recommendations.
Access is the promise; clinical fit is the test
OpenEvidence reported that U.S. clinicians consulted its platform 42 million times in August. Nadler also said several hundred million Americans would be treated in 2026 by a doctor who had used OpenEvidence to help guide care. Those figures describe use and expected reach in the United States; they do not establish that the international rollout will improve patient outcomes.
For clinicians who lack subscriptions to major medical journals, a tool that can surface evidence at the point of care could widen access to medical information. Dr. Ahmed Bendary, a cardiologist at Benha University in Egypt, called expanded access outside the United States and Europe “a tremendous leap forward,” particularly where institutional journal subscriptions are limited.
Anthropic President Daniela Amodei said the work needed philanthropic support because market incentives alone would not bring the service to low-resource regions. Whether the partnership can sustain free access, adapt recommendations to local treatment options and demonstrate benefits for patients remains unanswered. The rollout’s immediate test is whether clinicians in the named countries can use it in the conditions where care is delivered.